Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Imugene Ltd (IMU)

Sydney
Currency in AUD
Disclaimer
0.085
+0.014(+19.01%)
Closed
IMU Scorecard
Unusual trading volume
Fair Value
Unlock Value
Day's Range
0.0710.085
52 wk Range
0.0390.150
Bid/Ask
0.084 / 0.085
Prev. Close
0.071
Open
0.072
Day's Range
0.071-0.085
52 wk Range
0.039-0.15
Volume
44,148,418
Average Volume (3m)
14,444,683
1-Year Change
-42.22%
Shares Outstanding
7,319,810,809
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell

People Also Watch

1.655
IFM
-2.65%
0.355
IMM
0.00%
0.022
VMS
0.00%
0.675
M7T
+2.27%
0.200
FFX
0.00%
How do you feel today about IMU?
Vote to see community's results!
or

Imugene Ltd Company Profile

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company’s HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.